Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells 7,259 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Michael Chi sold 7,259 shares of the firm’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $43.28, for a total value of $314,169.52. Following the completion of the transaction, the insider now owns 193,601 shares in the company, valued at approximately $8,379,051.28. This represents a 3.61 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Michael Chi also recently made the following trade(s):

• On Friday, January 24th, Michael Chi sold 17,304 shares of Hims & Hers Health stock. The shares were sold at an average price of $31.00, for a total value of $536,424.00.
• On Friday, January 10th, Michael Chi sold 7,259 shares of Hims & Hers Health stock. The shares were sold at an average price of $24.07, for a total value of $174,724.13.
• On Tuesday, December 24th, Michael Chi sold 17,303 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.97, for a total value of $483,964.91.
• On Thursday, December 19th, Michael Chi sold 7,500 shares of Hims & Hers Health stock. The shares were sold at an average price of $26.00, for a total value of $195,000.00.
• On Tuesday, December 10th, Michael Chi sold 7,259 shares of Hims & Hers Health stock. The shares were sold at an average price of $32.25, for a total value of $234,102.75.
• On Monday, December 2nd, Michael Chi sold 2,054 shares of Hims & Hers Health stock. The shares were sold at an average price of $33.56, for a total value of $68,932.24.

Hims & Hers Health Price Performance

HIMS stock traded down $1.21 during mid-day trading on Tuesday, reaching $43.56. The company had a trading volume of 7,309,816 shares, compared to its average volume of 11,847,643. The stock has a 50 day simple moving average of $30.50 and a two-hundred day simple moving average of $23.43. The company has a market capitalization of $9.52 billion, a price-to-earnings ratio of 99.01 and a beta of 1.35. Hims & Hers Health, Inc. has a 52 week low of $9.14 and a 52 week high of $46.01.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. SlateStone Wealth LLC grew its stake in Hims & Hers Health by 4.0% in the fourth quarter. SlateStone Wealth LLC now owns 10,640 shares of the company’s stock valued at $257,000 after purchasing an additional 413 shares in the last quarter. Blume Capital Management Inc. grew its stake in Hims & Hers Health by 100.0% in the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after purchasing an additional 600 shares in the last quarter. Quest Partners LLC grew its stake in Hims & Hers Health by 22.6% in the third quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock valued at $81,000 after purchasing an additional 807 shares in the last quarter. Harbour Investments Inc. grew its stake in Hims & Hers Health by 18.8% in the fourth quarter. Harbour Investments Inc. now owns 5,269 shares of the company’s stock valued at $127,000 after purchasing an additional 833 shares in the last quarter. Finally, Stonekeep Investments LLC grew its stake in Hims & Hers Health by 5.5% in the fourth quarter. Stonekeep Investments LLC now owns 16,952 shares of the company’s stock valued at $410,000 after purchasing an additional 882 shares in the last quarter. 63.52% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have weighed in on HIMS. Deutsche Bank Aktiengesellschaft increased their target price on Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research note on Wednesday, November 6th. Canaccord Genuity Group increased their target price on Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a research note on Monday, December 2nd. Needham & Company LLC increased their target price on Hims & Hers Health from $28.00 to $31.00 and gave the company a “buy” rating in a research note on Monday, January 6th. Citigroup lowered Hims & Hers Health from a “neutral” rating to a “sell” rating and increased their target price for the company from $24.00 to $25.00 in a research note on Friday, January 10th. Finally, TD Cowen reissued a “buy” rating and issued a $28.00 target price on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $25.13.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.